Dipti Patel‐Donnelly
About
Dipti Patel‐Donnelly is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics.
According to data from OpenAlex, Dipti Patel‐Donnelly has authored 27 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pathology and Forensic Medicine, 11 papers in Oncology and 9 papers in Genetics. Recurrent topics in Dipti Patel‐Donnelly's work include Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Multiple Myeloma Research and Treatments (6 papers). Dipti Patel‐Donnelly is often cited by papers focused on Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Multiple Myeloma Research and Treatments (6 papers). Dipti Patel‐Donnelly collaborates with scholars based in United States, Canada and Netherlands. Dipti Patel‐Donnelly's co-authors include Christopher A. Yasenchak, Ralph V. Boccia, Jeff P. Sharman, Sarit Assouline, Youram Nassir, Mark Knapp, Ori Yellin, Alberto Bessudo, Donald Gravenor and James R. Berenson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.
In The Last Decade
Dipti Patel‐Donnelly
27 papers receiving 430 citations
Peers
Dipti Patel‐Donnelly
David H. Vesole United States
Nadine Juge‐Morineau France
Lixia Pei United States
Evgenii A. Osmanov Russia
Jordan A. Herst Canada
Alma María Rodríguez United States
Christopher A. Yasenchak United States
Nilima Parry‐Jones United Kingdom
Sverker Hasselblom Sweden
Eugene Zhu United States
Citations per year, relative to Dipti Patel‐Donnelly Dipti Patel‐Donnelly (= 1×)
peers
David H. Vesole
Countries citing papers authored by Dipti Patel‐Donnelly
Since
Specialization
Citations
This map shows the geographic impact of Dipti Patel‐Donnelly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dipti Patel‐Donnelly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dipti Patel‐Donnelly more than expected).
Fields of papers citing papers by Dipti Patel‐Donnelly
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Dipti Patel‐Donnelly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dipti Patel‐Donnelly. The network helps show where Dipti Patel‐Donnelly may publish in the future.
Co-authorship network of co-authors of Dipti Patel‐Donnelly
This figure shows the co-authorship network connecting the top 25 collaborators of Dipti Patel‐Donnelly. A scholar is included among the top collaborators of Dipti Patel‐Donnelly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dipti Patel‐Donnelly. Dipti Patel‐Donnelly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Friedberg, Jonathan W., Rodolfo Bordoni, Dipti Patel‐Donnelly, et al.. (2023). Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood. 143(9). 786–795.
2.
Yasenchak, Christopher A., Rodolfo Bordoni, Dipti Patel‐Donnelly, et al.. (2023). Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E). Blood. 142(Supplement 1). 4435–4435.
3.
Yasenchak, Christopher A., Rodolfo Bordoni, Dipti Patel‐Donnelly, et al.. (2022). Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E). Blood. 140(Supplement 1). 3685–3686.
4.
Yasenchak, Christopher A., Rodolfo Bordoni, Dipti Patel‐Donnelly, et al.. (2020). Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients. Blood. 136(Supplement 1). 18–19.
5.
Burke, John M., Andrei R. Shustov, James Essell, et al.. (2018). An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 18(8). e327–e331.
6.
Haas, Válerie de, Nofisat Ismaila, Anjali S. Advani, et al.. (2018). Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline. Journal of Clinical Oncology. 37(3). 239–253.
7.
Friedberg, Jonathan W., Andres Forero‐Torres, Beata Holkova, et al.. (2018). Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.. Journal of Clinical Oncology. 36(15_suppl). 7542–7542.
8.
Kim, Jane S., et al.. (2016). WALDENSTRÖM'S MACROGLOBULINEMIA MASQUERADING AS BIRDSHOT CHORIORETINOPATHY. Retinal Cases & Brief Reports. 11(2). 152–155.
9.
Westin, Jason R., Michael B. Maris, Ayad Al‐Katib, et al.. (2016). A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study.. Journal of Clinical Oncology. 34(15_suppl). TPS7577–TPS7577.
10.
Yasenchak, Christopher A., Andres Forero‐Torres, Rodolfo Bordoni, et al.. (2015). Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study. Blood. 126(23). 587–587.
11.
Yasenchak, Christopher A., Ahmad Halwani, Ranjana H. Advani, et al.. (2015). Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study. Blood. 126(23). 814–814.
12.
Bartlett, Nancy L., Charles M. Farber, Christopher A. Yasenchak, et al.. (2015). Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 33(15_suppl). 8506–8506.
13.
Berenson, James R., James Hilger, Ori Yellin, et al.. (2014). Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia. 28(7). 1529–1536.
14.
Yasenchak, Christopher A., Charles M. Farber, Lihua E. Budde, et al.. (2014). Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study. Blood. 124(21). 1745–1745.
15.
Berenson, James R., James Hilger, Robert Dichmann, et al.. (2013). Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).. Journal of Clinical Oncology. 31(15_suppl). 8599–8599.
16.
Sharman, Jeff P., Jerome H. Goldschmidt, John M. Burke, et al.. (2012). CD30 expression in nonlymphomatous malignancies.. Journal of Clinical Oncology. 30(15_suppl). 3069–3069.
17.
Berenson, James R., Ori Yellin, Robert Dichmann, et al.. (2012). A phase I/II study of carfilzomib (CFZ) as a replacement for bortezomib (BTZ) for multiple myeloma (MM) patients (Pts) progressing while receiving a BTZ-containing combination regimen.. Journal of Clinical Oncology. 30(15_suppl). 8098–8098.
18.
Berenson, James R., Ori Yellin, Alberto Bessudo, et al.. (2012). Phase I /II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. British Journal of Haematology. 160(3). 321–330.
19.
Berenson, James R., James Hilger, Robert Dichmann, et al.. (2012). A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen. Blood. 120(21). 4063–4063.
20.
Berenson, James R., Ori Yellin, Alberto Bessudo, et al.. (2011). Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study. Blood. 118(21). 1857–1857.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by David H. Vesole Breakdown of academic impact, for papers by Nadine Juge‐Morineau Breakdown of academic impact, for papers by Lixia Pei Breakdown of academic impact, for papers by Evgenii A. Osmanov Breakdown of academic impact, for papers by Jordan A. Herst Breakdown of academic impact, for papers by Alma María Rodríguez Breakdown of academic impact, for papers by Christopher A. Yasenchak Breakdown of academic impact, for papers by Nilima Parry‐Jones Breakdown of academic impact, for papers by Sverker Hasselblom Breakdown of academic impact, for papers by Eugene Zhu